FDA Inspection 1216183 — Fresenius Kabi USA LLC

Fresenius Kabi USA LLC — FEI 1450022

The FDA completed an inspection of Fresenius Kabi USA LLC on August 24, 2023 in Melrose Park, IL. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 1 citation was issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 24, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Melrose Park, IL (United States)

Citations

IDCFRDescription
110521 CFR 211.22(d)Procedures not in writing, fully followed